• Теги
    • избранные теги
    • Компании2244
      • Показать ещё
      • Показать ещё
      Страны / Регионы461
      • Показать ещё
      Международные организации41
      • Показать ещё
      • Показать ещё
      • Показать ещё
      • Показать ещё
21 июля, 18:56

Ironwood (IRWD) Reports Positive Data on Reflux Candidate

Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.

21 июля, 15:35

Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

Выбор редакции
21 июля, 11:00

AstraZeneca CEO reassures staff, aims to be at September cancer meet

AstraZeneca Chief Executive Pascal Soriot, responding to rumors he might leave the drugmaker to join rival Teva Pharmaceutical Industries, has told staff he expects to work together with employees to see the company succeed. A company spokeswoman added he was intending to attend the European Society for Medical Oncology (ESMO) annual meeting in Madrid in September, assuming that AstraZeneca had clinical data on its new immunotherapy medicine ready to present at the event. Soriot did not comment on whether he had received a job offer from Teva in the internal memo to staff, which was sent out at the start of this week.

18 июля, 00:47

AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

17 июля, 22:11

Arena Announces Secondary Stock Worth $150M (revised)

Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.

17 июля, 20:38

Британию захлестнула онкология. Почему это плохо для Украины и России

Англичане обвиняют в экоциде Monsanto, которая идет в «незалежную»

Выбор редакции
15 июля, 00:47

Pascal Soriot to remain at AstraZeneca

Chief executive to present earnings on July 27, scotching rumours of move to rival Teva

Выбор редакции
Выбор редакции
14 июля, 17:57

Pfizer Xeljanz Label Expansion Application Accepted by FDA

Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.

14 июля, 17:22

J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab

Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.

14 июля, 14:28

Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.

Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.

Выбор редакции
14 июля, 13:05

AstraZeneca's silence on CEO helps wipe out 3 billion pounds

Uncertainty over the future of AstraZeneca (AZN.L) Chief Executive Pascal Soriot drove the Anglo-Swedish drugmaker's shares lower again on Friday, taking the cost of two days of silence to more than 3 billion pounds. AstraZeneca has repeatedly declined to comment on an Israeli media report on Wednesday that said the well-regarded Soriot was in talks to join Israel's Teva Pharmaceutical Industries (TEVA.TA), the world's biggest generic drugmaker. AstraZeneca shares closed 3.5 percent lower on Thursday and were down 2.5 percent on Friday at a two-month low after the company said it would not comment on rumours or speculation.

Выбор редакции
14 июля, 10:50

FTSE 100 slips as builders and Royal Mail shares drop

The London market lost ground on Friday, with Royal Mail and house builders seeing some of the biggest falls.

14 июля, 00:37

Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion

We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.

Выбор редакции
Выбор редакции
13 июля, 21:58

AstraZeneca: mystique

One can see why chief executive Pascal Soriot might be tempted to move on

13 июля, 21:21

Post-Brexit London is open for business (no matter how grubby)

The City watchdog’s rewriting of the premium listing rules to accommodate a potential mega-listing in London of Aramco is deplorableNow we know how the City will be kept open for business after Brexit. If a foreign government, in this case Saudi Arabia’s royal family, doesn’t like the rules in London, the UK is happy to be flexible.For some, the Financial Conduct Authority’s proposed rewrite of the listing rules to woo state-backed companies is a fuss about nothing. Aramco is an enormous beast that will shower fees on bankers and lawyers, and maybe also burnish London’s standing. It could easily float here under a so-called “standard” listing if it wished. But, if the price of keeping it away from New York is a tweak to the definition of a prestige “premium” listing, so be it. Continue reading...

Выбор редакции
13 июля, 20:43

Ocado gains on prospect of automation cutting costs

FTSE 100 edges lower as AstraZeneca loses steam

Выбор редакции
13 июля, 20:04

AstraZeneca shares hit by report on chief’s departure

Israeli newspaper says Pascal Soriot plans to leave drugmaker to join Teva